Drug Manufacturer Submission Deadlines

Welcome to the iDBL

Important Submission Information

July 2025

The following information provides details on effective dates and deadlines for submitting Drug Product submissions to the Alberta Drug Benefit List (ADBL) for 2025 - 2026.

The following dates may be subject to change; however, you will be notified accordingly if such a change occurs.

Deadlines for Expedited Reviews of Biosimilar and Interchangeable Drug Products

ADBL Effective Date Deadlines for Complete Submissions
September 1, 2025 July 25, 2025
October 1, 2025 August 25, 2025
November 1, 2025 September 25, 2025
December 1, 2025 October 24, 2025
February 1, 2026 November 28, 2025
March 1, 2026 January 26, 2026
May 1, 2026 March 25, 2026
June 1, 2026 April 24, 2026
July 1, 2026 May 25, 2026
August 1, 2026 June 25, 2026
September 1, 2026 July 24, 2026
October 1, 2026 August 25, 2026

Deadlines for all other Drug Product Submission Categories

ADBL Effective Date Deadlines for Complete Submissions
September 1, 2025 June 10, 2025
November 1, 2025 August 11, 2025
February 1, 2026 October 10, 2025
March 1, 2026 December 10, 2025
May 1, 2026 February 10, 2026
July 1, 2026 April 10, 2026
September 1, 2026 June 10, 2026
November 1, 2026 August 10, 2026

Manufacturers should note that only complete submissions, satisfying all the submission requirements of the applicable category of Drug Product received by 4:30 p.m. Mountain Standard / Daylight Savings Time (as applicable) on the deadline, will be put forward for consideration by the Expert Committee on Drug Evaluation and Therapeutics or Expedited Review, as applicable. There is no guarantee that every completed submission will be reviewed and/or a recommendation made at the next scheduled meeting of the Expert Committee.

Alberta Price Confirmation Tentative Dates

The Alberta Price Confirmation (APC) is issued prior to an ADBL publication. The APC is a requirement for listing on the ADBL. The APC Tentative Issue Dates are subject to change.

ADBL Effective Date APC Tentative Issue Date
February 1, 2026 December 1, 2025
March 1, 2026 February 2, 2026
April 1, 2026 To Be Confirmed
May 1, 2026 April 2, 2026
June 1, 2026 May 1, 2026
July 1, 2026 June 2, 2026
August 1, 2026 July 3, 2026
September 1, 2026 July 31, 2026
October 1, 2026 September 1, 2026
November 1, 2026 October 6, 2026
December 1, 2026 November 2, 2026

Correspondence

Manufacturers may provide submissions for consideration for potential addition to the Alberta Drug Benefit List (ADBL) via email to the following address: submissions@ab.bluecross.ca

Submissions sent to other email addresses will not be considered for potential addition to the ADBL. It is recommended that manufacturers place the drug name(s) and strength(s) of the submitted product(s) in the subject header in order to ensure that multiple emails can be easily associated with one another.

Manufacturers are reminded that hard copies of submissions must follow by mail and should be sent to the attention of:

Manager

Scientific and Research Services

Alberta Blue Cross®

10009 – 108 Street NW

Edmonton AB T5J 3C5

A copy of covering correspondence and summary documents only should be forwarded to:

Executive Director

Pharmaceutical and Health Benefits

Primary and Preventative Health Services

11th Floor, 10025 Jasper Avenue

Edmonton AB T5J 1S6

Questions or Comments

Questions or comments regarding the drug review process or submission deadlines can be addressed to:

Coordinator

Scientific and Research Services

Alberta Blue Cross®

10009 – 108 Street NW

Edmonton AB T5J 3C5

Phone: 780-498-8098

Fax: 780-498-3534

Email: submissions@ab.bluecross.ca

Notice:

The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross® who publishes them on behalf of the Government of Alberta.

Government of Alberta reserves the right to make changes, without notice, to the List through the Interactive DBL (iDBL), and any such changes to the Interactive DBL (iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.